Scancell Holdings plc (LON:SCLP – Get Free Report) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 13.76 ($0.17) and traded as low as GBX 10 ($0.12). Scancell shares last traded at GBX 10 ($0.12), with a volume of 906,872 shares traded.
Scancell Stock Performance
The company has a debt-to-equity ratio of 61.41, a current ratio of 3.42 and a quick ratio of 13.01. The company has a market cap of £92.96 million, a PE ratio of -1,000.00 and a beta of 0.35. The stock has a 50 day simple moving average of GBX 12.72 and a two-hundred day simple moving average of GBX 13.76.
About Scancell
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
Recommended Stories
- Five stocks we like better than Scancell
- What is a Stock Market Index and How Do You Use Them?
- 3 Legacy Tech Companies Reemerging as AI Leaders
- How to Most Effectively Use the MarketBeat Earnings Screener
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- What Are Dividend Achievers? An Introduction
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
